Heidelberg, Germany – June 05, 2008 – Affimed Therapeutics AG, a biopharmaceutical company focused on the development of antibody therapeutics, today announced that it has appointed Volker Lang, Ph.D., as its Chief Business Officer.
Dr. Lang joins Affimed from Scil Technology where he was Vice President of Corporate Development. At Scil Technology, he was responsible for the commercial development of a portfolio of regenerative medicine products including an eye-catching deal with Pfizer earlier this year. In his 16 years experience in the biotechnology sector, spanning basic research, industrial R&D, Business Development & Licensing, and commercial operations & management, Dr. Lang contributed significantly in the scientific development and commercialization of biological agents for industrial and healthcare applications.
“Dr. Lang’s has broad scientific knowledge and extensive experience in the sector of Business Development as well as his dynamic approach will be of great benefit to Affimed,” said Rolf H. Günther, MD PhD, Chief Executive Officer of Affimed. “This is particularly important as our product portfolio is now entering a very interesting phase with several milestones coming up”.
“Affimed has a strong track record in antibody research and a team assembled to translate that into commercial success,“ said Dr. Volker Lang, the new Chief Business Officer of Affimed. “I am excited and feel privileged to be joining the company at this pivotal stage.”
Dr. Lang replaces Gavin D Clark who has been working as VP Business Development for the last 2 years. Mr Clark is a founding partner at Procela Partners Limited and he will be continuing to consult for a number of early stage Biotech and Discovery Science based companies both in EU and US.
Dr. Lang combines a background as scientist and project manager with extensive experience in the commercialisation of biotechnology products. He has also gained considerable CMC/Production experience in his previous positions. Dr. Lang received his Ph.D. from the Technical University of Brunswick. After that he worked as an industry scientist and project manager with UCB-Celltech and Fresenius-Kabi, respectively. He joined Cosmix GmbH, Brunswick as Head of Business Development, and later Chief Operating Officer. Following Cosmix and prior to joining Scil Technology he was Vice President of Business Development at Pieris Proteolab AG.
About Affimed Therapeutics AG
Affimed is a private biopharmaceutical company based in Heidelberg, Germany specialising in the development of recombinant antibodies - the fastest growing segment of the pharmaceutical industry. Affimed was founded in May 2000 by Professor Melvyn Little as a spin-off of his group »Recombinant Antibodies« at the German Cancer Research Centre in Heidelberg. By utilizing its broad portfolio of proprietary, in-house technology platforms together with crucial enabling freedom-to-operate licenses, the company has been able to establish a pre-clinical product pipeline of promising novel product candidates mainly for indications in oncology and autoimmune diseases. To learn more about Affimed please visit www.affimed.com.
Dr Rolf Günther
Chief Executive Officer
Affimed Therapeutics AG
t: +49 (0)6221 65307 20
Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill Life Sciences
t : +49 (0)89 57 00 18 06